Skip to main content
Premium Trial:

Request an Annual Quote

Roche NimbleGen, Sigma-Aldrich Set Co-marketing Pact

NEW YORK (GenomeWeb News) – Roche NimbleGen said today that it has aligned its chromatin immunoprecipitation-on-microarrays (ChIP-chip) with Sigma Aldrich's GenomePlex whole-genome amplification technology, and the companies will co-market the technologies together.

Researchers can use the two platforms together to study the genome for epigenetic interactions between DNA and DNA-binding proteins to find out what regions are transcriptionally active or repressed, and the mechanisms that regulate these processes, Roche said.

The companies plan to publish protocols for ChIP-chip research and will provide technical support to assist researchers integrating the two platforms, and each company will co-market the products together.

The firms did not disclose financial or other terms of the alliance.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.